Winston R. Brown, Jr. Joins Alexza Pharmaceuticals as Vice President, Quality

Winston R. Brown, Jr. Joins Alexza Pharmaceuticals as Vice President, Quality

PR Newswire

MOUNTAIN VIEW, Calif., April 17, 2014

MOUNTAIN VIEW, Calif., April 17, 2014 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today that Winston R. Brown, Jr. has joined the
Company as Vice President, Quality. Mr. Brown brings more than two decades of
experience in global quality, regulatory compliance and development operations
working with diverse biopharmaceuticals, medical devices and nutritionals in
globally integrated companies. In this position, Mr. Brown has primary
responsibility for Quality Assurance, Quality Control and Quality Systems.

Alexza Pharmaceuticals. (PRNewsFoto/Alexza Pharmaceuticals, Inc.)

"With the ongoing commercialization of ADASUVE in the U.S. and EU, and
commercial collaborations in place with Teva and Ferrer, it is an exciting
time to join Alexza," said Mr. Brown. "I look forward to working with
Alexza's talented employees to continue the transition from a development
stage company to commercial stage company."

"We are pleased to welcome Winston to our team," said Robert A. Lippe,
Executive Vice President, Operations and Chief Operations Officer at
Alexza."Winston brings extensive quality program expertise coupled with
strong operational leadership experience to our company, at a time of exciting
growth in both scale and scope. We look forward to his contributions in
support of our efforts with the global ADASUVE launch and in expanding our
candidate pipeline."

From December 2011 to April 2014, Mr. Brown served as Global Head, Quality R&D
- Pharmaceuticals, Biologics, and Vision Care Devices at Alcon Research, Ltd.,
a division of Novartis. Mr. Brown was the Executive Director, Global Quality
Compliance for Baxter Healthcare International from November 2009 to December
2011. From January 2008 to October 2009, Mr. Brown was with Bausch & Lomb as
its Director of Site Quality - Vision Care-Sterile Ophthalmic Solutions. Mr.
Brown previously held multiple leadership positions in quality
systems/compliance, regulatory affairs, and process validation with Holopack
Pharmaceuticals, USA and J&J Consumer Pharmaceuticals. Prior to entering the
private healthcare industry, Mr. Brown served as an Officer in the United
States Army, where he held various operational roles including Laboratory
Officer in Clinical Pathology at Walter Reed Army Medical Center. Mr. Brown
holds an M.S. degree in Pharmaceutical Engineering from Stevens Institute of
Technology, an M.B.A. from Cameron University - University of Oklahoma, a B.S.
in Microbiology & Operations Management from Concord University and a Medical
Technology degree from George Washington University.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions. Alexza's products are based on the
Staccato^® system, a hand-held inhaler designed to deliver a drug aerosol to
the deep lung, providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.

ADASUVE is Alexza's first commercial product. It has been approved for sale
by the U.S. Food and Drug Administration and the European Commission. Teva
Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the
U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for
ADASUVE in Europe, Latin America and the Commonwealth of Independent States.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,

Safe Harbor Statement
This news release contains forward-looking statements that involve significant
risks and uncertainties. Any statement describing the Company's expectations
or beliefs is a forward-looking statement, as defined in the Private
Securities Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of developing and commercializing
drugs, including the ability of Alexza and its partners, Teva and Ferrer, to
effectively and profitably commercialize ADASUVE, estimated product revenues
and royalties associated with the sale of ADASUVE, the adequacy of the
Company's capital to support the Company's operations, and the Company's
ability to raise additional funds and the potential terms of such potential
financings. The Company's forward-looking statements also involve assumptions
that, if they prove incorrect, would cause its results to differ materially
from those expressed or implied by such forward-looking statements. These and
other risks concerning Alexza's business are described in additional detail in
the Company's Annual Report on Form 10-K for the year ended December 31, 2013
and the Company's other Periodic and Current Reports filed with the Securities
and Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.

Logo -

SOURCE Alexza Pharmaceuticals, Inc.

Contact: Thomas B. King, President and CEO, 650.944.7634,,
Mark K. Oki, SVP, Finance and CFO, 650.944.7666,
Press spacebar to pause and continue. Press esc to stop.